Enrique Zudaire

Caribou Biosciences (United States) — United States

Medicine · Health Sciences

40h-index8.9kcitations169works6.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(57), Multiple Myeloma Research and Treatments(30), Biosimilars and Bioanalytical Methods(25), Neuropeptides and Animal Physiology(19), Pancreatic function and diabetes(15)

Publications168 total

A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)
The Journal of Rheumatology·2025Open Access
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
Journal of Clinical Oncology·2024· 12 cited
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
Journal of Clinical Oncology·2024· 8 cited
Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up
Blood·2023· 8 cited
P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2023· 3 cited
POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2023· 2 cited
MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
POSTER: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
Oral Abstract: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Clinical Lymphoma Myeloma & Leukemia·2023
MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Clinical Lymphoma Myeloma & Leukemia·2023
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
Clinical Lymphoma Myeloma & Leukemia·2023· 12 citedOpen Access
S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere·2023· 12 citedOpen Access
S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
HemaSphere·2023· 2 citedOpen Access
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
Journal of Clinical Oncology·2023· 30 cited
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine·2023· 618 citedOpen Access
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Journal of Clinical Oncology·2023· 107 cited
B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
HemaSphere·2023· 1 citedOpen Access
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
HemaSphere·2023Open Access
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
Journal for ImmunoTherapy of Cancer·2023· 19 citedOpen Access
Supplemental Figures 1-8 from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Frank Cuttitta(17), Jordan M. Schecter(12), Deepu Madduri(10), Andrzej Jakubowiak(10), Sundar Jagannath(10), Jesús G. Berdeja(9), Saad Z. Usmani(9), Adam D. Cohen(9), Tzu‐Min Yeh(9), Arnob Banerjee(9), Carolyn C. Jackson(9), Alfredo Martı́nez(9), Alicia J. Allred(8), Yunsi Olyslager(7), Jeffrey L. Goldberg(7), Brad St. Croix(7), Mounzer Agha(6), William Deraedt(6), Dong Geng(6), Muhammad Akram(6)